Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Quick Stats
Jan 30, 202652.9
AI Score
HOLD0.37
Volume Ratio
Feb 12, 2026
Next Earnings
18
+ve Days (30d)
12
-ve Days (30d)
VNDA Stock Summary
Last updated Jan 30, 2026
VNDA is currently trading at $7.54, positioned above its 200-day moving average of $5.16, indicating a long-term uptrend. The stock has a 52-week range of $3.8092 to $9.6.
Technical Analysis: The 50-day moving average stands at $6.76, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 51.062, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.088, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates VNDA at 52.9/100 with a HOLD recommendation.
VNDA (Vanda Pharmaceuticals Inc.) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 51.062 |
| CMF (20) | -0.088 |
| ROC (10) | 1.208 |
| ADX (14) | 34.503 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.255 |
| AROONOSC (14) | 57.143 |
| WILLAMS %R (14) | -63.203 |
| MFI (14) | 49.096 |
VNDA Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
VNDA Price vs Max Options Open Interest
VNDA Max Change In Options Open Interest
VNDA Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
VNDA Daily Out of Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
VNDA Daily In the Money Options - Sort by Max open Interest (near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
VNDA Most Active Options by Volume(near term)
31st January 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Vanda Pharmaceuticals Inc. is above both 50 Day and 200 Day SMA which is considered Bullish.
VNDA Moving Averages Analysis
Vanda Pharmaceuticals Inc. has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jan 30, 2026
Vanda Pharmaceuticals Inc. has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jan 30, 2026
VNDA (Vanda Pharmaceuticals Inc.) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 7.8 |
| 20 | 7.77 |
| 30 | 7.55 |
| 50 | 6.76 |
| 100 | 5.82 |
| 200 | 5.16 |
VNDA Fundamental Analysis
| P/E (Forward) | 103.0928 |
| P/E (Trailing) | -- |
| Market Cap ($) | 454.5 million |
| Earnings/Share ($) | -1.44 |
| Net Proft Margin (%) | -0.397 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -2.6725 |
| EPS Estimate Next Year ($) | -1.4475 |
| WallStreet Target Price ($) | 13.625 |
| Most Recent Quarter |
Vanda Pharmaceuticals ($VNDA) is experiencing a surge in stock price after turning down a buyout offer before approval and now trading in the $8 range. The approval of NEREUS™ for motion-induced vomiting has validated its pharmacological profile, leading to further exploration of NK-1 antagonism. Vanda is advancing tradipitant for gastroparesis and prevention of nausea induced by GLP-1 receptor agonists. The company anticipates launching NEREUS™ in the coming months and is committed to expanding its therapeutic potential. Investors are expecting the stock to reach double digits next week, with some predicting a price target of $15 by Friday.
Updated 2025-12-31 21:00:02